Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ERBB2 Gene Amplification”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT04818333
What this trial is testing

SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer

Who this might be right for
Advanced Non-small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd. 157
Testing effectiveness (Phase 2)Study completedNCT00356811
What this trial is testing

Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer

Who this might be right for
Neoplasms, Breast
GlaxoSmithKline 57
Early research (Phase 1)Ended earlyNCT03410927
What this trial is testing

TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities

Who this might be right for
Advanced Solid Tumors With HER2 AbnormalitiesAdvanced Solid Tumors With HER3 Abnormalities
Taiho Oncology, Inc. 19
Testing effectiveness (Phase 2)UnknownNCT04179656
What this trial is testing

The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor

Who this might be right for
Solid TumorHER2 Gene MutationHER-2 Gene Amplification+1 more
Tianjin Medical University Second Hospital 100
Testing effectiveness (Phase 2)Looking for participantsNCT04879329
What this trial is testing

Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Who this might be right for
Urothelial Carcinoma
Seagen, a wholly owned subsidiary of Pfizer 372
Testing effectiveness (Phase 2)UnknownNCT04215159
What this trial is testing

Trastuzumab Biosimilar (Samfenet®) Plus Treatment of Physician's Choice (TPC) in Patients With HER2-positive Solid Tumor

Who this might be right for
HER-2 Protein OverexpressionHER-2 Gene Amplification
Jin-Hee Ahn 42
Large-scale testing (Phase 3)Looking for participantsNCT06282575
What this trial is testing

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Who this might be right for
Biliary Tract Cancer
Jazz Pharmaceuticals 286
Not applicableUnknownNCT00874146
What this trial is testing

Level of HER2-neu Gene Amplification an Response to Trastuzumab

Who this might be right for
Advanced Breast Cancer
Istituto Clinico Humanitas 100
Testing effectiveness (Phase 2)UnknownNCT03225937
What this trial is testing

Evaluation of Trastuzumab in Combination With Lapatinib or Pertuzumab in Combination With Trastuzumab-Emtansine to Treat Patients With HER2-positive Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Fondazione del Piemonte per l'Oncologia 54
Not applicableEnded earlyNCT03137693
What this trial is testing

Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer

Who this might be right for
Breast CancerBreast Cancer FemaleBreast Adenocarcinoma
H. Lee Moffitt Cancer Center and Research Institute 20
Testing effectiveness (Phase 2)Study completedNCT03602079
What this trial is testing

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Who this might be right for
HER2-positive Breast CancerHER2 Gene MutationHER-2 Gene Amplification+41 more
Klus Pharma Inc. 49
Testing effectiveness (Phase 2)UnknownNCT03418558
What this trial is testing

Study of Trastuzumab-emtansine in Patients With HER2-positive Metastatic Colorectal Cancer Progressing After Trastuzumab and Lapatinib.

Who this might be right for
Metastatic Colorectal Cancer
Fondazione del Piemonte per l'Oncologia 13
Testing effectiveness (Phase 2)Ended earlyNCT00748709
What this trial is testing

Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.

Who this might be right for
Neoplasms
Boehringer Ingelheim 20
Testing effectiveness (Phase 2)Study completedNCT02004769
What this trial is testing

Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer

Who this might be right for
Stomach NeoplasmsNeoplasms MetastasisERBB2 Gene Amplification
Sun Yat-sen University 67
Testing effectiveness (Phase 2)Study completedNCT03365882
What this trial is testing

S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

Who this might be right for
Colon AdenocarcinomaERBB2 Gene AmplificationRectal Adenocarcinoma+16 more
SWOG Cancer Research Network 240
Testing effectiveness (Phase 2)UnknownNCT05170256
What this trial is testing

Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients

Who this might be right for
Esophageal Squamous Cell CarcinomaHER-2 Protein OverexpressionHER-2 Gene Amplification
Morten Mau-Sørensen 24
Large-scale testing (Phase 3)Looking for participantsNCT05786716
What this trial is testing

DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations

Who this might be right for
Haematological MalignancyColorectal NeoplasmsUrinary Bladder Neoplasm+8 more
Cancer Research UK 30
Early research (Phase 1)UnknownNCT04660929
What this trial is testing

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

Who this might be right for
HER2-positiveAdenocarcinomaBile Duct Cancer+28 more
Carisma Therapeutics Inc 48
Testing effectiveness (Phase 2)UnknownNCT05135715
What this trial is testing

RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)

Who this might be right for
Melanoma, Stage IIHER2-positiveAdvanced Melanoma
RemeGen Co., Ltd. 50
Testing effectiveness (Phase 2)Ended earlyNCT03630809
What this trial is testing

Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1

Who this might be right for
Breast CancerHER2-positive Breast CancerHER-2 Gene Amplification+4 more
H. Lee Moffitt Cancer Center and Research Institute 16
Next Page